

# Co-operative surgical trial for gastric cancer

<b>Submission date</b> 28/02/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/02/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 21/01/2019	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr James Lyddiard

**Contact details**  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA  
-  
abc@email.com

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
ST01

## Study information

**Scientific Title**

Co-operative surgical trial for gastric cancer

**Study objectives**

To compare the effectiveness of more radical (R2) resection to the R1 resection with respect to the endpoints.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Not Specified

**Participant information sheet**

**Health condition(s) or problem(s) studied**

Cancer

**Interventions**

Arm 1: conventional (R1) resection of tumour.

Arm 2: radical (R2) resection of tumour.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

1. Operative morbidity and mortality (within 6 weeks of surgery)
2. Post-operative sequelae
3. Survival - with and without evidence of cancer
4. Local recurrence
5. Site and distribution of metastatic disease

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/01/1986

**Completion date**

01/11/1993

## **Eligibility**

**Key inclusion criteria**

Histologically or cytologically proven invasive gastric adenocarcinoma (stage I-III).

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

400

**Key exclusion criteria**

The patient must not have a perforated gastric carcinoma requiring emergency surgery.

**Date of first enrolment**

01/01/1986

**Date of final enrolment**

01/11/1993

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**MRC Clinical Trials Unit**

London

United Kingdom

NW1 2DA

# Sponsor information

## Organisation

Medical Research Council (MRC) (UK)

## Sponsor details

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

## Sponsor type

Research council

## Website

<http://www.mrc.ac.uk>

# Funder(s)

## Funder type

Research council

## Funder Name

Medical Research Council (MRC) (UK)

## Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	preliminary results	13/04/1996		Yes	No
<a href="#">Results article</a>	5-year survival results	01/03/1999		Yes	No